相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators
Alexandru-Emil Matei et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator The VICTORIA Trial
Paul W. Armstrong et al.
JACC-HEART FAILURE (2018)
Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling
Connor A. Emdin et al.
CIRCULATION (2018)
The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review
Peter Sandner et al.
GERONTOLOGY (2017)
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
Burkert Pieske et al.
EUROPEAN HEART JOURNAL (2017)
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study
Gerasimos Filippatos et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
Marius M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure
Markus Follmann et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Meeting report of the 8th International Conference on cGMP cGMP: generators, effectors, and therapeutic implications at Bamberg, Germany, from June 23 to 25, 2017
Andreas Friebe et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2017)
Thiol-Based Redox Modulation of Soluble Guanylyl Cyclase, the Nitric Oxide Receptor
Annie Beuve
ANTIOXIDANTS & REDOX SIGNALING (2017)
FIRST-IN-HUMAN SINGLE-ASCENDING-DOSE STUDY OF IW-1973, A NEW SOLUBLE GUANYLATE CYCLASE STIMULATOR
John Hanrahan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?
A. Kovacs et al.
NETHERLANDS HEART JOURNAL (2016)
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
Takashi Nakai et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial
Hossein-Ardeschir Ghofrani et al.
LANCET RESPIRATORY MEDICINE (2016)
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial
Gerald Simonneau et al.
LANCET RESPIRATORY MEDICINE (2016)
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
Clara Dees et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence
Johannes-Peter Stasch et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells
Christoph Zenzmaier et al.
EXPERIMENTAL CELL RESEARCH (2015)
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction The SOCRATES-REDUCED Randomized Trial
Mihai Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling
Christian Beyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smoke-induced Pulmonary Hypertension and Emphysema
Norbert Weissmann et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size
Justin S. Bice et al.
CARDIOVASCULAR RESEARCH (2014)
Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)
Burkert Pieske et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Riociguat Reduces Infarct Size and Post-Infarct Heart Failure in Mouse Hearts: Insights from MRI/PET Imaging
Carmen Methner et al.
PLOS ONE (2013)
Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis
Christian Beyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Structure and Regulation of Soluble Guanylate Cyclase
Emily R. Derbyshire et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 81 (2012)
The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
Michaela Lang et al.
PLOS ONE (2012)
The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
Jennifer C. Irvine et al.
PLOS ONE (2012)
Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats
Sandra Geschka et al.
PLOS ONE (2011)
Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
Oleg V Evgenov et al.
BMC Pharmacology & Toxicology (2011)
Animal Models of Systemic Sclerosis Prospects and Limitations
Christian Beyer et al.
ARTHRITIS AND RHEUMATISM (2010)
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
H. A. Ghofrani et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models
Yuliya Sharkovska et al.
JOURNAL OF HYPERTENSION (2010)
Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart
Soban Umar et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2010)
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension
F. Grimminger et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart
Hiroyuki Masuyama et al.
HYPERTENSION RESEARCH (2009)
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
Emily J. Tsai et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension
R. T. Schermuly et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521:: An ascending-dose study in healthy male volunteers
Reiner Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase
Torsten R. Dunkern et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Nitric oxide and peroxynitrite in health and disease
Pal Pacher et al.
PHYSIOLOGICAL REVIEWS (2007)
Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs
Cristiane F. Freitas et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2007)
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats
Hiroyuki Masuyama et al.
HYPERTENSION (2006)
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling
R Dumitrascu et al.
CIRCULATION (2006)
Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
Andrew T. Bender et al.
PHARMACOLOGICAL REVIEWS (2006)
The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP Levels in hippocampal slices
K Rutten et al.
BEHAVIOURAL BRAIN RESEARCH (2005)
Intracellular cyclic nucleotide analogues inhibit in vitro mitogenesis and activation of fibroblasts derived from obstructed rat kidneys
TD Hewitson et al.
NEPHRON EXPERIMENTAL NEPHROLOGY (2004)
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs
OV Evgenov et al.
CIRCULATION (2004)
Cyclic nucleotide research - still expanding after half a century
JA Beavo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
NO- and haem-independent activation of soluble guanylyl cyclase:: molecular basis and cardiovascular implications of a new pharmacological principle
JP Stasch et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat
J Prickaerts et al.
NEUROSCIENCE (2002)
Nitric oxide attenuates the expression of transforming growth factor-β3 mRNA in rat cardiac fibroblasts via destabilization
N Abdelaziz et al.
HYPERTENSION (2001)
分享论文
